



Fig 1. Atezolizumab was administered at a fixed dose of 1,200 mg intravenously on day 1 every 3 weeks in all cohorts. TC3 or IC3 = TC 50% or IC 10% PD-L1-expressing cells, respectively; TC2/3 or IC2/3 = TC or IC 5% PD-L1-expressing cells, respectively. 1L, first line; 2L, second line; 3L, third line; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; IC, tumor-infiltrating immune cells; IHC, immunohistochemistry; INV, investigator; IRF, independent review facility; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; TC, tumor cells.